Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002583 · ClinicalTrials.gov registry record · Phase 3
Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed
A Phase 3 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 482
- Enrollment target
NCT00002583 is a Phase 3 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 482 participants.
The verdict
NCT00002583, a Phase 3 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 482 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy is more effective than no further treatment for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of vinorelbine plus cisplatin with that of no further therapy in treating patients who have stage I or stage II non-small cell lung cancer that has been completely removed during surgery.
Interventions
- DRUG cisplatin
- DRUG vinorelbine ditartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 482 participants |
| Start Date | 1994-07-07 |
| Est. Completion | 2009-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002583
The ClinicalTrials.gov registry entry for NCT00002583 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 482 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.
NCT00002583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002583 about?
NCT00002583 is a clinical study titled "Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy is more effective than no further treatment for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effe...
What is the current status of trial NCT00002583?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 482 participants. The study started on 1994-07-07. Estimated completion is 2009-12-21.
What interventions are being tested in trial NCT00002583?
The interventions under investigation include: cisplatin (DRUG), vinorelbine ditartrate (DRUG).
Who is sponsoring clinical trial NCT00002583?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.